DIAGNOS Welcomes Dr. Pierre-Luc Charlebois to its Advisory Board

DIAGNOS Inc. (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in utilizing Artificial Intelligence for the early detection of critical health issues, has announced that Dr. Pierre-Luc Charlebois has joined its Advisory Board. The addition of Dr. Charlebois, an orthopedic surgeon from Quebec, along with other esteemed advisory members—Dr. Tomas J. Philipson, former vice-chairman of the White House Council of Economic Advisers; Mr. Ed Weiner, a seasoned entrepreneur; and Dr. Barry A. Ginsberg, an optometrist—aims to enhance the Corporation's growth and strategic direction.

Dr. Charlebois holds an orthopedic surgery degree from the University of Montreal and a master’s degree in Health Economics, Policy and Management from the London School of Economics. His expertise in the Canadian healthcare system and rich background in both medical practice and business are expected to provide vital insights to DIAGNOS’s management team.

André Larente, President and CEO of DIAGNOS, expressed his enthusiasm about Dr. Charlebois’s appointment, emphasizing that he is confident the orthopedic surgeon's subject matter expertise will significantly bolster the company’s expansion efforts.

DIAGNOS is dedicated to improving diagnostic accuracy and patient outcomes through the integration of AI technologies in the healthcare sector, particularly for eye-related health problems. The company’s vision is to streamline workflows for healthcare clinicians while offering extensive data for better health decision-making.

For further details about the company and its innovations, visit www.diagnos.com and www.sedarplus.com. The news release also contains forward-looking statements, and the company disclaims any intention to update these unless required by law.

DIAGNOS Inc.'s recent appointment of Dr. Pierre-Luc Charlebois to its Advisory Board signifies a strategic advancement in the company's expansion within the healthcare sector. Dr. Charlebois, with his rich background as an orthopedic surgeon and expertise in health economics, is poised to enhance DIAGNOS's strategic direction, particularly in navigating the complexities of the Canadian healthcare system.

The incorporation of advanced AI technology positions DIAGNOS favorably in the burgeoning field of health diagnostics. As the demand for efficient and accurate diagnostic solutions escalates, the company's commitment to early detection of critical eye-related health problems is particularly timely. The collaboration with experienced advisors, including notable figures like Dr. Tomas J. Philipson and Ed Weiner, strengthens DIAGNOS's potential to scale its innovations.

Investors should watch for how this advisory board reshapes DIAGNOS’s strategic initiatives. The expertise brought in by such professionals not only aids in product development but also in effectively communicating the value proposition to healthcare providers and potential partners. Furthermore, their insight could bolster DIAGNOS’s market penetration strategies and funding opportunities.

While the health tech market presents substantial growth opportunities, it is essential to recognize the inherent volatility and competitive dynamics within the sector. DIAGNOS's strategic moves, like the appointment of Dr. Charlebois, could signal positive developments for the company. However, as indicated in their forward-looking statements, investors should remain cautious regarding future projections and be mindful of market conditions that may affect the company's performance.

In summary, DIAGNOS presents an intriguing opportunity for investors interested in healthcare innovation. The strategic enhancements and advisory additions could spur growth, but careful consideration of market risks and ongoing developments will be essential for informed decision-making.